NF-κB is a potential pharmacological target in triple negative breast cancers.

D’Alessandro, N

Research output: Contribution to conferencePaper

Abstract

Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20% to 25% of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.
Original languageEnglish
Publication statusPublished - 2015

Fingerprint

Triple Negative Breast Neoplasms
Pharmacology
Breast Neoplasms
Epithelial-Mesenchymal Transition
Progesterone Receptors
Estrogens
Neoplasm Metastasis
Drug Therapy
Therapeutics
Neoplasms

Cite this

NF-κB is a potential pharmacological target in triple negative breast cancers. / D’Alessandro, N.

2015.

Research output: Contribution to conferencePaper

@conference{213882af498a46fe9bf62c6141020d94,
title = "NF-κB is a potential pharmacological target in triple negative breast cancers.",
abstract = "Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20{\%} to 25{\%} of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.",
keywords = "NF-κB, triple negative breast cancers",
author = "{D’Alessandro, N} and Natale D'Alessandro and Manuela Labbozzetta and Nicoletta Vivona and {Notarbartolo Di Villarosa}, Monica and Paola Poma",
year = "2015",
language = "English",

}

TY - CONF

T1 - NF-κB is a potential pharmacological target in triple negative breast cancers.

AU - D’Alessandro, N

AU - D'Alessandro, Natale

AU - Labbozzetta, Manuela

AU - Vivona, Nicoletta

AU - Notarbartolo Di Villarosa, Monica

AU - Poma, Paola

PY - 2015

Y1 - 2015

N2 - Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20% to 25% of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.

AB - Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20% to 25% of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.

KW - NF-κB, triple negative breast cancers

UR - http://hdl.handle.net/10447/225599

M3 - Paper

ER -